{
    "clinical_study": {
        "@rank": "60333", 
        "arm_group": [
            {
                "arm_group_label": "Arm S", 
                "arm_group_type": "No Intervention", 
                "description": "sorafenib 400mg bid daily po until progression"
            }, 
            {
                "arm_group_label": "Arm C", 
                "arm_group_type": "Experimental", 
                "description": "after the first Conventional Transarterial Chemoembolization is completed, sorafenib po and cTACE on demand until progression"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, multi-center, open-labeled, phase III study in patients with advanced\n      HCC. A total of 338 patients will be randomized (1:1) into one of the two treatment arms, to\n      receive sorafenib with (Arm Combination-treatment; Arm C) or without (Arm Sorafenib alone\n      treatment; Arm S) cTACE.\n\n      All the patients will be initially given sorafenib within 72 hours after the randomization.\n      Treatment should continue until the criteria for treatment discontinuation are met.\n\n      After the treatment period, patients will undergo follow up for survival every 12 weeks (\u00b17\n      days) from the last dose, and the survival follow up will be performed for at least 1.5\n      years after the last patient's last treatment."
        }, 
        "brief_title": "A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Adult Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "The superiority of the Arm C (cTACE+Sorafenib) over the Arm S (Sorafenib) in the OS period\n      will be verified in the ITT set and FAS using a stratified log-rank test. Stratification\n      factors consist of mUICC stage (III vs. IV), Vascular invasion (none and Vp1-2 vs. Vp3-4 and\n      any other presence), Child-Pugh score (5 vs. 6-7), serum AFP level (\u2265200 ng/mL vs. <200\n      ng/mL). The significance level is 5% (one-sided)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        To be eligible to participate in the study, patients must meet the following criteria:\n\n          1. Signed written informed consent\n\n          2. Clinical or histological diagnosis of HCC based on the guidelines of the Korean Liver\n             Cancer Study Group and the National Cancer Center Korea\n\n          3. At least one typical enhanced index lesion in the liver that is bi-dimensionally\n             measurable by multiphasic spiral CT scan or dynamic contrast-enhanced MRI, and size\n             of largest tumor is 15 cm or less at enrollment.\n\n          4. Tumor conditions confirmed by abdominal imaging (contrast enhanced CT \u00b1 MRI) and\n             chest imaging (CT) performed within 4 weeks prior to the treatment initiation:\n\n          5. Age of at least 20 years.\n\n          6. ECOG Performance Status of 0, 1 or 2.\n\n          7. Child-Pugh class A or B (Child-Pugh score \u2264 7).\n\n          8. Life expectancy of at least 16 weeks.\n\n          9. Adequate bone marrow, liver, and renal function as assessed by the following\n             laboratory requirements (no transfusion, no restoration), conducted within 14 days\n             prior to screening:\n\n         10. Female patients at least 1 year postmenopausal, surgically sterile or those of\n             childbearing potential must have a negative urine pregnancy test within 14 days prior\n             to the first treatment, and have to use at least one medically acceptable and\n             effective contraceptive method for the last 2 months prior to Screening Visit:\n             methods of effective contraception result in a low failure rate (i.e. less than 1%\n             per year) when used consistently and correctly such as a barrier method (implant,\n             injectable contraceptives, oral contraceptives, intrauterine contraceptive device),\n             hormonal IUD, sexual abstinence or vasectomized partner.\n\n        Exclusion Criteria:"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "338", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01829035", 
            "org_study_id": "STAH Korea Trial"
        }, 
        "intervention": {
            "arm_group_label": "Arm C", 
            "description": "Concurrent use of the following material/drug is defined as cTACE in this trial.\nEmbolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil\nAnti-tumor drug:\nUnapproved drug/embolization material from each regulatory agency should not be used.\nTo chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed", 
            "intervention_name": "Conventional Transarterial Chemoembolization (cTACE)", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "TACE", 
            "Sorafenib"
        ], 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "contact": {
                "email": "eunahcho98@ncc.re.kr", 
                "last_name": "Eun-Ah Cho", 
                "phone": "+82 10 5052 7198"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "National Cancer Center, Korea"
            }, 
            "investigator": {
                "last_name": "Joong-Won Park, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study)", 
        "overall_contact": {
            "email": "jwpark@ncc.re.kr", 
            "last_name": "Joong-Won Park, Ph.D", 
            "phone": "+82 10-8996-9930"
        }, 
        "overall_official": {
            "affiliation": "National Cancer Center, Korea", 
            "last_name": "Joong-Won Parkr, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The overall survival (OS) of oral sorafenib given as monotherapy daily compared to sorafenib with combination cTACE in subjects", 
            "safety_issue": "No", 
            "time_frame": "3.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01829035"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Cancer Center, Korea", 
            "investigator_full_name": "Joong-Won Park", 
            "investigator_title": "Chief of Hepatology, Center for Liver Cancer", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to progression (TTP)in patients", 
                "safety_issue": "No", 
                "time_frame": "3.5 years"
            }, 
            {
                "measure": "Tumor response rate (TRR)in patients", 
                "safety_issue": "No", 
                "time_frame": "3.5 years"
            }, 
            {
                "measure": "Progression free survival(PFS)will be evaluated", 
                "safety_issue": "No", 
                "time_frame": "3.5 years"
            }, 
            {
                "measure": "Evaluation of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "3.5 years"
            }
        ], 
        "source": "National Cancer Center, Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Center, Korea", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}